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Abstract
Background: Although chronic myeloid leukemia (CML) treatment has improved since the introduction of imatinib
mesylate (IM), cases of resistance have been reported. This resistance has been associated with the emergence of
multidrug resistance (MDR) phenotype, as a BCR-ABL independent mechanism. The classic pathway studied in MDR
promotion is ATP-binding cassette (ABC) family transporters expression, but other mechanisms that drive drug
resistance are largely unknown. To better understand IM therapy relapse due to the rise of MDR, we compared the
proteomic profiles of K562 and Lucena (K562/VCR) cells.
Results: The use of 2-DE coupled with a MS approach resulted in the identification of 36 differentially expressed
proteins. Differential mRNA levels of leucine-rich PPR motif-containing (LRPPRC) protein, minichromosome
maintenance complex component 7 (MCM7) and ATP-binding cassette sub-family B (MDR/TAP) member 1 (ABCB1)
were capable of defining samples from CML patients as responsive or resistant to therapy.
Conclusions: Through the data presented in this work, we show the relevance of MDR to IM therapy. In addition,
our proteomic approach identified candidate actors involved in resistance, which could lead to additional
information on BCR-ABL-independent molecular mechanisms.
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Background
Chronic myeloid leukemia (CML) is a myeloproliferative
disease, and the BCR-ABL constitutive tyrosine kinase
(TK), an oncoprotein, serves as a marker of this condition.
This oncoprotein is responsible for the pathogenesis of
CML and is the primary molecular target for disease ther-
apy [1]. Although CML treatment has improved with the
development of imatinib mesylate (IM, Glivec
®, Gleevec -
Novartis), a TK inhibitor, some patients fail to respond to
this therapy [2]. Resistance to treatment was first related
to BCR-ABL-dependent mechanisms, such as mutations
of the BCR-ABL kinase site. However, mutations are not
seen in all patients who are resistant to IM treatment.
This suggests that other resistance mechanisms occur in
these patients. Among these mechanisms, known as BCR-
ABL-independent mechanisms, is the multidrug resistance
(MDR) phenotype [3-9]. MDR is known to be the major
cause of failure in cancer treatment and has a multifactor-
ial origin. It is related to the expression of ATP-binding
cassette (ABC) family transporters such as P-glycoprotein
(Pgp-ABCB1), breast cancer related protein (BCRP-
ABCG2) and multiresistance protein (MRP-ABCC1)
[10,11]. Despite the identification and knowledge of ABC
transporters, the resulting pathways involved in MDR rise
in IM resistance, causing leukemic cells to become resis-
tant to therapy remain uncharacterized. Proteomic ana-
lyses by both 2-DE and MS-based methods have been
widely used in comparative studies of protein expression
patterns in cells or organisms in attempts to identify pro-
teins involved in diverse maladies, including different
types of cancer [12-18]. In an attempt to identify other
proteins that could be associated with an IM therapy
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pared the proteomic profiles of the K562 (an erythroleuke-
mic) cell line and the Lucena (K562/VCR - vincristine) cell
line in our study. Initially, we showed that Lucena cells
exhibit cross-resistance to IM. Than, using 2-DE and
MALDI-TOF-TOF MS, we identified 36 differentially
expressed proteins between these two cell lines. In silico
characterization of the identified proteins showed that
detoxification pathways and cellular maintenance biofunc-
tions were increased in the resistant cell line. We selected
over-expressed genes in resistant cells for quantitative vali-
dation in healthy donors and CML patients with different
responses to IM therapy. The leucine-rich PPR motif-con-
taining (LRPPRC) protein, minichromosome maintenance
complex component 7 (MCM7) and ATP-binding cassette
sub-family B (MDR/TAP) member 1 (ABCB1) genes were
able to differentiate CML patients as either resistant or
s e n s i t i v et oI Mt h e r a p y .T h r o u g ht h ed a t ap r e s e n t e di n
this work, we show that MDR is closely associated with
resistance to IM and demonstrate its importance as a
prognostic indicator for CML patients. Moreover, this pro-
teomic approach identified LRPPRC and MCM7 as possi-
ble new targets associated with IM resistance.
Results
Differential IM response in CML cell lines
Lucena cells were established from K562 cells as a mul-
tidrug resistance lineage by vincristine (VCR) selection
and their pattern of resistance includes a range of che-
motherapy drugs [19]. Real time quantitative PCR (RT-
qPCR) analysis of K562 and Lucena cell lines showed an
800.0-fold increase of ABCB1 mRNA levels by Lucena
cells compared to K562 cells (Figure 1A). Over-expres-
sion of Pgp protein level was examined by flow cytome-
try and we observed a 45.0-fold increase expression of
Pgp in Lucena cells compared to parental cells (Figure
1B-C). As demonstrated by Assef and colleagues, K562
cells managed to exhibit a MDR phenotype through
VCR treatment also presented cross-resistance to IM
[20]. Because the development of MDR cell lines is not
well described in the literature (i.e., different concentra-
tions of chemotherapy drugs are used) and VCR mainte-
nance concentrations differ among these cell lines, we
investigated IM effectiveness in Lucena cells. We treated
both cell lines with different concentrations of the drug
for 24 h and assayed cell viability. A comparative analy-
sis of the viability of K562 and Lucena cells after IM
treatment with 0.1 μM, 0.2 μM, 0.5 μM, 1 μM, 2 μM, 5
μMa n d1 0μM doses showed that Lucena cells were
more resistant to IM than K562 cells (inhibitory concen-
tration - IC50 5 μMa n d1μM, respectively; Figure 2A).
To prove that the different cell viabilities were due to
differential apoptotic activation between the cellular
lineages, we conducted Annexin V assays with both cell
lines under IM treatment with 1 μM( K 5 6 2I C 50 dose).
The results (Figure 2B) revealed that an IM dose of 1
μM activates apoptosis in approximately 20% of K562
cells but in only approximately 5% of Lucena cells. This
result indicates that a 1 μMd o s eo fI Mf o r2 4hi s
insufficient to induce apoptosis in Lucena cells (Figure
2C) as it does in K562 cells. Moreover, cell cycle assay
showed that IM treatment induced arrest in G0/G1 in
both cell lines. However, this effect was more pro-
nounced in K562 cells compared to Lucena cells
(35.42% and 25.35%, respectively). Furthermore, we
investigated the mRNA levels of BCR-ABL and the most
related drug transporters involved in cancer with the
goal of identifying the cause of Lucena cells cross-resis-
tance to IM. In addition to possessing more ABCB1/Pgp
than K562 cells (Figure 1), Lucena cells also had more
BCR-ABL and OCT1 mRNA (Figure 2D), but did not
presented significant difference in ABCG2 mRNA levels,
which indicates that the failure of IM to induce apopto-
sis in Lucena cells may be due to Pgp drug efflux and/
or by BCR-ABL up-regulation. In other to verify that
cross-resistance to IM by Lucena cells might be through
Figure 1 ABCB1/Pgp expression levels in K562 and Lucena
cells. (A) RT-qPCR analysis of ABCB1 mRNA levels. Raw
expression values were normalized to b-actin expression. (B) Pgp
expression by flow cytometry, represented as MRFI. (C)
Representative histograms of Pgp expression. (1): K562 cells and (2):
Lucena cells. PE-isotype antibody was used as control. Values
represent the means of three independent determinations ± s.d (*p
< 0.05)
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activity assays on Lucena cells treated in 3 different con-
ditions: 1 μMI M ,5 0μM Verapamil (VP - Pgp blocker)
and co-treated with 1 μM IM and 50 μM VP (Figure 3).
VP treatment was not toxic and did not induce apopto-
sis (Figure 3A) and cell cycle arrest (Figure 3B) com-
pared to control (untreated cells). Co-treatment
enhanced cell cycle arrest in 10%, compared to IM
alone (Figure 3B), which was followed by a 3.0-fold
increase (approximately) in apoptosis compared to IM
alone (Figure 3A). Rhodamine 123 (Rho 123) retention
confirmed that K562 cells did not present functional
Pgp efflux pump, even after IM treatment (Figure 3C-
D). This accumulation was not verified in Lucena cells
in both control (untreated cells) and IM treatment (Fig-
ure 3C-D), demonstrating that Pgp pump was functional
in these cells. After VP treatment, irrespective of IM
presence, Pgp was blocked, showing that Rho 123 was
able to accumulate in these cells (Figure 3C-D).
Identification of 2-DE differentially expressed proteins
Because the Lucena cell line has a cross-resistance to IM,
we sought to generate Lucena and K562 cell lines (without
IM treatment) proteomic profiles to understand the differ-
ences that contribute to IM cross-resistance. 2-DE was
performed using 900 μg of total protein extract from each
cell line. The 2-DE gels had more than 80% similarity, and
294 and 295 protein spots were visualized in the K562 and
Lucena samples, respectively (Figure 4). All protein spots
were excised from the 2-DE gels, digested with trypsin and
analyzed by MALDI-TOF-TOF MS. Four hundred
seventy-seven proteins were identified using this approach
(235 proteins in K562 and 242 proteins in Lucena), which
resulted in an identification rate of more than 80%. After
an ImageMaster comparative analysis, only spots showing
greater than 2.0 fold between samples (resistant versus
responsive) were considered differentially expressed. In
this analysis 36 proteins were found to be differentially
expressed, with 14 proteins down-expressed and 22 pro-
teins over-expressed in Lucena cells. Quantitative differ-
ences were observed, and proteins were analyzed and
separated into cellular classes according to their potential
biological function by gene ontology (GO) analyses http://
www.geneontology.org (Table 1). Information regarding 2-
DE analysis can be found in Additional file 1.
In silico analysis of identified proteins
To better understand resistance biology and to select
the most promising candidates for further investiga-
tion, we assessed proteins using Ingenuity Pathway
Figure 2 Panel of Lucena cross-resistance to IM treatment.( A) K562 and Lucena cell lines were treated with a range of IM doses for 24 h.
Cell viability was measured by trypan blue exclusion assay. Apoptotic cells (B) and cell cycle (C) were measured by flow cytometry after 1 μMo f
IM treatment in both cell lines. (D) ABCG2, OCT1 and BCR-ABL mRNA expression levels in K562 and Lucena cell lines were quantified by RT-qPCR.
Expression values were normalized to b-actin expression. Values represent the means of three independent determinations ± s.d. (*p < 0.05; **p
< 0.01; ***p < 0.001)
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Page 3 of 17Figure 3 Lucena cells cross-resistance to IM is due Pgp efflux. Apoptotic cells (A), cell cycle (B) and Rho 123 (C-D) were measured by flow
cytometry after 3 different treatments conditions: 1 μM IM, 50 μM VP and co-treatment with 1 μM IM and 50 μM VP. (D) Representative
histograms of Rho 123 extrusion under conditions described above. (1): K562 ctrl and IM treatment; (2): Lucena ctrl and (3) Lucena under: IM, VP
and IM + VP treatments. K562 cells were used as positive control for Rho 123 retention, and K562 treated with 1 μM IM was used as positive
control for apoptosis induction and cell cycle arrest. Values represent the means of three independent determinations ± s.d. (*p < 0.05; **p <
0.01). AF = auto fluorescence; K5 = K562; LU = Lucena.
Figure 4 Proteome maps of K562 (A) and Lucena (B) cell lines.N i n eh u n d r e dm i c r o g r a m so ft o t a lp rotein extract were separated by
electrophoresis on IPG (pH 4-7) and gradient (8-18%) SDS-PAGE gels. 2-DE gels were stained with coomassie colloidal blue (CBB). The migration
of molecular mass markers is represented in the middle. Numbers refer to the spot identity used in table 1. Arrows correspond to the
differentially expressed proteins according to ImageMaster 2D Platinum software.
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Spot N° Identified Protein Fold Change > 2
(Ratio Lucena vs. K562)
a
Structural Proteins
INCREASE
1 L MSN Moesin 2.23
2 L RPSA 33 kDa protein 3.45
3 L ACTB Actin, cytoplasmic 1 2.75
DECREASE
1 K LCP1 Plastin-2 - 3.65
Stress Response/Chaperone
INCREASE
4 L HSP90B1 Endoplasmin precursor 2.22
5 L HSPB1 Heat shock protein beta-1 4.23
6 L HSP90AB1 Heat shock protein HSP 90-beta 3.1
7 L HYOU1 Hypoxia up-regulated protein 1 precursor 3.76
8 L VCP Transitional endoplasmic reticulum ATPase 2.29
DECREASE
2 K HSP90AB1 Heat shock protein HSP 90-beta - 4.17
Nucleic Acid Binding, Synthesis, Stability
INCREASE
9 L AARS Alanyl-tRNA synthetase, cytoplasmic 3.43
10 L RPA3 Replication protein A 14 kDa subunit 2.82
11 L RBM17 Splicing factor 45 2.54
12 L LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial precursor 3.18
DECREASE
3 K LSM2 U6 snRNA-associated Sm-like protein LSm2 - 3.23
4 K HNRNPF Heterogeneous nuclear ribonucleoprotein F - 3.01
5 K HNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 - 3.22
Protein Binding and Synthesis
INCREASE
13 L EIF3K Eukaryotic translation initiation factor 3 subunit K 2.96
DECREASE
6 K EIF1AY Eukaryotic translation initiation factor 1A, Y-chromosomal - 2.48
7 K RPS12 ribosomal protein S12 -3.74
8 K HINT1 Histidine triad nucleotide-binding protein 1 -3.57
Metabolism
INCREASE
14 L ARG2 Arginase-2, mitochondrial precursor 3.83
15 L COX6B1 Cytochrome c oxidase subunit VIb isoform 1 3.15
16 L CKB Creatine kinase B-type 2.1
DECREASE
9 K ATP5B ATP synthase subunit beta, mitochondrial precursor - 2.83
10 K TPI1 Isoform 1 of Triosephosphate isomerase - 3.96
Signaling Transduction
INCREASE
17 L SH3BGRL SH3 domain-binding glutamic acid-rich-like protein 3.04
18 L TXNDC17 Thioredoxin domain-containing protein 17 2.68
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® Systems, http://www.inge-
nuity.com). We only analyzed direct interactions of
increased and decreased proteins (Lucena vs. K562)
separately and compared these analyses. The identified
proteins were then clustered into two major networks
(Figures 5, 6), as well as broader biofunctional groups
and canonical pathways, by IPA (Figures 7, 8). The
created networks indicated Cellular Function and
Maintenance (p=5.77E-8 - 3.97E-02, 8 molecules);
Cell Death (p=2.86E-06 - 4.55E-02, 14 molecules);
DNA Replication, Recombination, and Repair (p=
2.18E-04 - 3.84E-02, 5 molecules); Cell-to-Cell Signal-
ing and Interaction (p=1.29E-03 - 3.34E-02, 3 mole-
cules) and Small Molecule Biochemistry (p=1.29E-03
- 3.34E-02, 7 molecules) as the most relevant molecu-
lar and cellular functions increased in resistance.
Figure 5 Network analysis of down-expressed proteins involved in resistance. The biological network was generated after the protein’s
dataset was uploaded into IPA. Gray nodes denote uploaded proteins, and white nodes denote proteins from the IPA database. Lines between
the nodes indicate direct protein-protein interactions. Arrowheads show the direction of interaction. Self-regulation is indicated by lines that
begin and end on the same node.
Table 1 Proteome map of differentially expressed proteins in K562 and Lucena cell lines. (Continued)
19 L GMFB GMFB protein 2.89
20 L CAPNS1 Calpain small subunit 1 2.37
DECREASE
11 K STRAP Serine-threonine kinase receptor-associated protein - 3.22
Cell cycle/Proliferation
INCREASE
21 L MCM7 Isoform 1 of DNA replication licensing factor MCM7 4.02
22 L S100A11 Protein S100-A11 3.15
Unknown
DECREASE
12 K C19orf10 UPF0556 protein C19orf10 precursor - 3.12
13 K MTPN Myotrophin - 2.98
14 K C1QBP Complement component 1 Q subcomponent-binding protein, mitochondrial - 2.37
a Fold change > 2 in resistance: cell lines have constitutively increased or decreased at least 2.0-fold changes of the given protein. Values expressed by ratio
mean: Lucena/K562 (resistance versus responsive)
The corresponding spots on 2DE gels were identified with MS/MS
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shown in gray, and they are sometimes present in
more than one biofunctional group. The down-
expressed protein dataset did not provide as many sta-
tistical results on predominant canonical pathways
(Figure 7A) as the up-expressed protein dataset. How-
ever, it is known that the Fructose and Mannose Meta-
bolism pathway is down-regulated in the MDR
phenotype [21]. Aryl Hydrocarbon Receptor (AHR) Sig-
naling (p=2.68E-05), Cell Cycle Control of Chromoso-
mal Replication (p = 5.57E-04), Urea Cycle and
Metabolism of Amino Groups (p = 7.85E-04), Aldoster-
one Signaling in Epithelial Cells (p = 9.86E-04) and
Mitotic Roles of Polo-Like Kinase (p = 2.83E-03), were
the top five canonical pathways represented by the
over-expressed proteins in resistant cells. NRF2-
mediated Oxidative Stress Response (p=2.25E-04) and
Aryl Hydrocarbon Receptor (AHR) Signaling (p =
4.57E-05) were considered the top pathways in the
Toxicity List, also assessed by IPA analysis.
Validation of target genes by real-time quantitative PCR
Across a variety of possible candidates for validation, we
selected LRPPRC, MCM7 and RBM17 as representative
genes involved in the most representative molecular
functions identified by IPA. This validation approach
was selected due to limited amounts of patient samples.
RT-qPCR methodology is a FDA-approved assay for
clinics. RT-qPCR analysis was carried out to evaluate
mRNA levels in cell lines (data not shown), healthy
donors, IM-responsive patients and IM-resistant
patients. Additionally, the expression of drug transpor-
ters such as ABCB1, ABCG2 and OCT1 was analyzed.
Figure 9 shows their relative mRNA levels after normali-
zation to b-actin. Analyses of drug transporters showed
a significant over-expression of the ABCB1 in resistant
patients. All genes selected from the proteomic
approach were transcriptionally over-expressed in CML
patients. After statistical analyses, only RBM17 did not
show a significant difference in mRNA expression levels
between healthy donors and IM-resistant CML patients.
Figure 6 Network analysis of over-expressed proteins involved in resistance. The biological network was generated after the protein’s
dataset was uploaded into IPA. Gray nodes denote uploaded proteins, and white nodes denote proteins from the IPA database. Lines between
the nodes indicate direct protein-protein interactions. Arrowheads show the direction of interaction. Self-regulation is indicated by lines that
begin and end on the same node.
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To determine if the expression of the drug transporters
and target genes found by the proteomic approach,
along with other variables, could indicate a response to
IM therapy, we performed univariate and multivariate
analyses with 14 CML patients (5 responsive and 9
resistant to IM therapy). We considered the following
variables: target genes verified by RT-qPCR, molecular
and cytogenetic response, disease phase (chronic, accel-
erated and blastic phases are denoted CP, AP and BP,
respectively) and duration of disease. We constructed a
receiver operating characteristic (ROC) curve to estab-
lish the cut-off point for each gene in order to
categorize all mRNA expression levels found by RT-
qPCR as either under or above these cut-off points.
Using multivariate analysis, we calculated the Expb for
each variable, which is how much of an increase above
basal level is necessary to increase the effect of each
gene associated with all the genes studied. Because the
increases of ABCB1, LRPPRC and MCM7 above their
basal levels were statistically significant (Table 2), our
analyses suggested these genes as important variables
when analyzing IM therapy response. Their ROC curves
can be found in the additional files data (see Additional
file 2). Taken together, expression of these genes may
correlate with response to IM therapy.
Figure 7 IPA analysis of proteins down-expressed in resistance.
(A) Canonical Pathways analysis. The top 5 canonical pathways, are
shown as determined by IPA. The y-axis shows the negative log of
the p-value. (B) Biofunction analysis. The top 5 biofunctions among
“Diseases and Disorders”, “Molecular and Cellular Functions” and
“Physiological System Development and Function” are shown as
determined by IPA. The y-axis shows the negative log of the p-
value.
Figure 8 IPA analysis of proteins over-expressed in resistance.
(A) Canonical Pathways analysis. The top 5 canonical pathways, are
shown as determined by IPA. The y-axis shows the negative log of
the p-value. (B) Biofunction analysis. The top 5 biofunctions among
“Diseases and Disorders”, “Molecular and Cellular Functions” and
“Physiological System Development and Function” are shown as
determined by IPA. The y-axis shows the negative log of the p-
value.
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lyses, only the target genes revealed by 2-DE, showed
statistical significance in define CML patient’st h e r a p y
status
Discussion
Although the molecular basis of BCR-ABL-dependent
mechanisms in IM resistance are well established (such
as BCR-ABL mutations and BCR-ABL amplification),
t h es a m ei sn o tt r u ef o rt h eB C R - A B L - i n d e p e n d e n t
mechanisms. The complexity of BCR-ABL independent
resistance has not led to targeted therapy development.
Instead, current approaches are focused on overcoming
resistance of the T315I mutation, targeting survival
pathways, and multi-kinase inhibitors [22]. Various cel-
lular mechanisms may be involved in the nature of cel-
lular resistance. Cells exposed to toxic compounds can
d e v e l o pr e s i s t a n c eb yan u m b e ro fm e c h a n i s m s
including increased amount of drug target, inhibition of
apoptosis, changes in gene expression that control cell
cycle, enhanced DNA repair, decreased drug uptake, or
increased detoxification [23]. Baran and colleagues have
pointed some important insights on IM resistance
mediated by anti-apoptotic signals. In IM-resistant cells
developed by their group, over-expression of Bcl-2 (anti-
apoptotic gene) led to mitochondrial membrane poten-
tial (MMP) increase [24]. Besides, they examined the
role of Sphingosine kinase-1 (SK-1)/sphingosine 1-phos-
phate (SP1) signaling in IM resistance. SK-1/SP1 activa-
tion can promote resistance of IM-induced apoptosis
through unbalance between the levels of C18-ceramide
(pro-apoptotic) and SP1 (anti-apoptotic) [25]. Recently,
they determined a novel mechanism in which SK1/SP1
mediates BCR-ABL1 stability and drug resistance by
protein phosphatase 2A modulation [26]. Constitutive
activation of downstream BCR-ABL signaling molecules
such as STAT3, STAT5A, Lyn, NF-kB, ERK1/2, and
AKT are also considered as independent mechanisms of
IM resistance. These molecules have been studied as
potential targets for overcoming resistance [27-29].
Mencalha and colleagues demonstrated that LLL3, a
STAT3 inhibitor, led to a decrease in proliferation and
viability of BCR-ABL positive cells. As so, LLL3 admi-
nistered together with IM increased the sub-G1 DNA
content by 25% compared to IM treatment alone,
demonstrating an additive effect of IM-induced
Figure 9 Real-time quantitative PCR analysis of target gene expression in healthy donors and CML patients. Total RNA was isolated from
bone marrow donors and CML patients and examined by RT-qPCR to determine changes in mRNA levels. Raw expression values were
normalized to b-actin expression. Analyses of ABCB1, ABCG2, OCT1, RBM17, LRPPRC and MCM7 expression changes were performed in 6 donors, 5
IM-responsive patients and 9 IM-resistant patients. Values represent the means of three independent determinations ± s.d. (*p < 0.05). Resp. P =
responsive patients; Resist. P. = resistant patients.
Table 2 Multivariate analyses of IM therapy failure.
Genes ExpB 95% CI P
a P2
b
ABCB1 18.865 0.83 - 425.88 0.041
LRPPRC 2.867E-10 1.170E-11- 7.027E-9 0.022 0.013
MCM7 6.897E9 6.897E9- 6.897E9 0.005
Abbreviation: ExpB, Exponential b; 95% CI, 95% confidence interval
a p < 0.05 was considered to be significant
b P2: Significance of all 3 genes together
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consensus in literature that these cells are intrinsically
resistant to TK inhibition [31-35]. Interesting, Hamilton
and colleagues have shown recently in transgenic mouse
model of CML-like disease and in derived CML stem
cells from patients, that CML stem cell survival is BCR-
ABL kinase independent. They suggest that curative
approaches in CML must focus on kinase-independent
mechanisms of resistance [36].
Despite these novel information regarding BCR-ABL
independent mechanisms, MDR phenotype still remains
poorly understood. Little is known about the mechan-
isms through which MDR is activated, the molecules
that are being induced, the pathways that are altered
and exactly which proteins contribute to IM resistance.
It is possible that the MDR phenotype functions in the
same way for all drugs, but it is also possible that speci-
fic accessory proteins play important roles in resistance
to distinct and unrelated drugs.
Recently, some groups have demonstrated that K562
cells driven to acquire the MDR phenotype also pre-
sented cross-resistance to IM compared to their parental
cell lines [37]. This phenomenon is not exclusive by
VCR selection in vitro. Illmer and colleagues [38]
observed, in a model of K562-VP16 (etoposide) cells, a
gradually increasing in Pgp expression with subsequent
decline of intracellular IM levels. Decreased IM levels
were associated with a retained phosphorylation pattern
of the BCR-ABL target CRKL and loss of effect of IM
on cellular proliferation and apoptosis. Yamada and col-
leagues [39] showed similar results related to IM effec-
tiveness in K562-ADM (adriamycin) cells over-
expressing Pgp. Pgp over-expression impact on cellular
concentration of IM (and others TK inhibitors) was
shown by Haouala and colleagues by knocking-down
Pgp and measuring intra/extracellular IM ratio [40].
According to Vasconcelos and colleagues [41], an IM
treatment at different concentrations for 24 h in K562
and Lucena cells was sufficient to increase ABCB1 at
mRNA levels and Pgp protein levels only in Lucena
cells. Based on these data, we ought to investigate IM
effect on cellular viability, apoptosis and cell cycle. As
showed in Figure 2A, after 24 h of IM treatment,
Lucena cells presented an IC50 of 5 μM, which is 5.0-
fold greater than K562 cells’ IC50. These findings corro-
borate with Vasconcelos and colleagues’ observation
that Lucena cells over-express Pgp at 5 μM, compared
to control (untreated cells). This variation of Pgp could
explain Lucena cells’ viability under IM treatment and
the delay in apoptosis and cell cycle arrest in G0/G1,
compared to K562 cells (Figure 2B-C). Moreover, our
r e s u l t ss u m m a r i z e di nF i g u r e3p r o v i d ee v i d e n c et h a t
blockage of Pgp pump, due to VP treatment, increased
apoptosis and cell cycle arrest induced by IM in Lucena
cells, demonstrating that cross-resistance to IM may be,
among others mechanisms, through Pgp drug efflux.
In order to identify proteins involved in BCR-ABL-
independent mechanisms through MDR, we used this
model in a comparative proteomic study between CML
K562 and Lucena (K562/VCR) cell lines. Proteomic
approaches such as 2-DE and MS enable the identifica-
tion of differentially expressed proteins. In addition,
these studies also provide pictures of alterations, making
possible to better comprehend the biology and mechan-
isms that lead to a cellular process under investigation.
Our proteomic study of K562 and Lucena cells identi-
fied 36 differentially expressed proteins. The diversity of
the proteins confirms that several pathways are deregu-
lated and act together to promote the development of
resistance. Among the pathways identified by IPA ana-
lyses as increased in resistance, we highlight the NF-E2-
related factor 2 (NRF2)-mediated oxidative stress
response and aryl hydrocarbon receptor (AHR) signal-
ing. The key transcription factors of these pathways are
Nrf2 and AHR, respectively. Through their translocation
into the nucleus and binding to their respective ele-
ments in targets genes, they promote up-regulation of
antioxidant and detoxification genes, stress response
genes, xenobiotic-metabolizing genes, genes involving
the ubiquitin-mediated proteassomal degradation sys-
tem, intracellular redox-regulating genes, genes control-
ling cell growth and genes encoding transporters, such
as ABC family members [42,43]. The relationship
between these pathways and chemoresistance in several
types of cancer is well known [44-46]. However, only
recently has NRF2 signaling been under investigation
for its association with BCR-ABL
+ cell IM resistance.
Ozawa and co-workers demonstrated that up-regulation
of NRF2 conferred IM resistance to KCL22 cells
through transcription of the g-GCS light subunit (g-
GCSl), a major determinant for glutathione (GSH)
homeostasis [47]. The role of GSH in IM resistance was
also discussed by Colavita and colleagues in another
proteomic study [48]. This same group also showed that
NRF2 up-regulation by HEME increased the IM IC50
without changing BCR-ABL kinase activity. NRF2
repression restored IM sensitivity. These results were
verified by Bonovolias and Tsiftsoglou in a study with
CML and acute myeloid leukemia BCR-ABL
+ cells
[49,50]. Thus, these findings highlight the importance of
investigating not only NRF2 but also the role of AHR
signaling in IM resistance with the aim of gaining addi-
tional knowledge on the mechanistic basis of IM
resistance.
The separate evaluation of networks allowed us to
observe that the increased proteins found due to resis-
tance by our approach are localized in the center of the
network. This result indicates that these proteins are
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involved with cellular proliferation/maintenance proteins
as key connecting proteins. It is clear that these interac-
tions can lead to cellular maintenance through cytoske-
letal changes that may confer alterations in cellular
organization, cell cycle and proliferation. These altera-
tions may give an adaptive advantage to resistant cells.
LRPPRC, MCM7 and RBM17 were chosen as represen-
tative genes involved in these cellular processes. Quanti-
tative results permitted the verification of a tendency of
increased expression of target gene mRNA levels in IM-
resistant patients compared to IM-responsive patients.
Multivariate analyses sorted ABCB1, LRPPRC and
MCM7 as statistically significant genes in IM therapy
status.
LRPPRC is an approximately 130 kDa protein that was
first identified as over-expressed in the human liver car-
cinoma cell line HepG2 [51]. This protein seems to be
involved in several intracellular processes such as home-
ostasis and microtubule alteration [52,53]. It seems that
LRPPRC may be related to transactivation of MDR
genes (ABCB1 and LRP)b yi n v M E Ds e q u e n c ei na c u t e
lymphoid leukemia [54]. Moreover, an anti-apoptotic
role for LRPPRC has been recently determined in hepa-
tocarcinoma cells [55]. In up-regulated network created
by IPA, LRPPRC interacts directly with BTF3 protein,
which forms a stable complex with RNA polymerase II
and is involved with regulation of transcription initia-
tion. BTF3 interacts with MYC protein, which has a
well-established role in cell proliferation and CML evo-
lution. Along, these information support the potential
role of LRPPRC in cell maintenance, proliferation, regu-
lation of transcription and apoptosis.
MCM7 protein belongs to a highly conserved group of
proteins that are essential for the initiation of DNA
replication and cell proliferation [56]. This protein can
be regulated by MYCN (v-myc myelocytomatosis viral
related oncogene, neuroblastoma derived - avian) tran-
scription factor in neuroblastoma [57]. Additionally,
there is evidence that ABCB1 can also be regulated by
MYCN in neuroblastoma [58,59]. This information is
relevant as we found that MCM7 was over-expressed
IM-resistant patients. MYCN could be regulating both
g e n e si nC M L ,s oo v e r e x p r e s s i o no fM C M 7c o u l db e
indirectly related to resistance. Alternatively, MCM7
m a yb ed i r e c t l yi n v o l v e di nr e s i s t a n c eb ya l t e r i n gD N A
repair function, as shown previously [60-62]. In IPA net-
work MCM7 was shown to interact with TLH1 and
ZNF121 proteins, which are involved in regulation of
transcriptional activity. As LRPPRC, MCM7 is also
implicated with resistance biofunctions found in our
study such as cellular maintenance, cell cycle control
and cell proliferation.
The involvement of ABCB1 in IM resistance is contro-
versial, but our results demonstrate that the ABCB1
gene was significantly over-expressed in IM-resistant
patients. The 9 IM-resistant patients in our study did
not have mutations at the ABL site, and 5 patients were
in the CP or AP stage. This result indicates that CML
patients in the BC stage are not the only individuals
that over-express this gene, as has been suggested in the
literature [63,64]. Ferrao and colleagues have shown that
the ABCB1 gene does not confer IM resistance in vitro
[65], but several studies have provided contradictory
results. Specifically, studies with patients have shown
that over-expression or polymorphisms of the ABCB1
gene can alter the response to therapy [66-72]. For this
reason, a hypothesis was derived that tried to explain
the relationship between ABCB1 over-expression and
IM resistance. This hypothesis was based on the fact
that ABCB1 is expressed in early primitive normal
hematopoietic stem cells [73,74] and can be over-
expressed in leukemic stem cells, which would aid in
maintenance of leukemia [75]. However, evidence shows
that silencing ABCB1 in leukemic stem cells does not
sensitize them to IM treatment in culture [76,77]. The
role of the ABCB1 gene in IM resistance remains
unclear. However, our findings, along with published
data, suggest that ABCB1 c o u l db ec o n s i d e r e dap r o g -
nostic factor for CML, as it is in acute myeloid
leukemia.
Identification of potentially useful proteomic-based
biomarkers must be validated in larger, well-defined ret-
rospective and prospective clinical studies, and these
combined efforts should result in identification of bio-
markers that will greatly improve early detection, prog-
nosis and prediction of treatment response [78].
In conclusion, our comparative proteomic approach
using CML MDR/IM cross-resistant cell line and its
parental cell line identified LRPPRC and MCM7 as
putative actors in IM resistance. These data were vali-
dated in healthy donors and CML patients with different
therapy responses. Altogether the expression of these
genes and ABCB1 could discriminate responsive and
resistant groups and the therapy state of patients. As we
analyzed a small patient cohort, we sought validation by
future prospective clinical studies to establish biomar-
ker’s application in treatment response prediction or in
follow-up monitoring.
Methods
Culture conditions
Lucena (a K562 multidrug-resistant cell line induced by
VCR) cells over-expressing the ABCB1 gene were kindly
provided by Dr. Vivian Rumjanek (Departamento de
Bioquímica Médica, Universidade Federal do Rio de
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line (K562) and its VCR-resistant derivative Lucena
were grown in RPMI 1640 medium supplemented with
10% fetal bovine serum FBS, 50 units/mL penicillin G,
50 μg/L streptomycin and 2 mM L-glutamine (all from
Invitrogen) at 37°C in a humidified atmosphere contain-
ing 5% CO2. Lucena medium was supplemented with 60
nM VCR (Sigma).
Imatinib mesylate treatment
Cell lines were exposed to different doses of IM dis-
solved in DMSO (Sigma-Aldrich) with final concentra-
tion of 0.5%. DMSO-treated cells were used as vehicle-
controls. Treatments were carried out in 12-well culture
plates for a period of 24 h with a cell density of 2.0 ×
10
5 cells/mL. IM concentrations of 0.1 μM, 0.2 μM, 0.5
μM, 1 μM, 2 μM, 5 μMa n d1 0μM were used for cell
viability assays. For apoptosis and cell cycle assays, a 1
μM IM dose was used. Cells were treated with 1 μM
IM, 50 μM VP [79] and co-treated with 1 μMI Ma n d
50 μM VP for apoptosis, cell cycle and Pgp activity
assays. K562 cells were used as positive control for Rho
123 retention and K562 cells treated with 1 μMI M
were used as positive control for apoptosis induction
and cell cycle arrest. All experiments were performed in
triplicate.
Pgp expression assay
To determine Pgp expression, we analyzed both cell
lines with anti-Pgp-PE (phycoerythrin) antibody (Beck-
man Coulter) according to manufacturer’s instructions.
Briefly, after treatment, 5.0 × 10
5 cells were harvested,
washed twice with cold PBS, resuspended in 1 mL PBS/
BSA (0.2% Azide, 1% BSA) and incubated for 15 min.
After incubation, cells were harvested and anti-Pgp-PE
(5 μL) was added, and the sample was incubated for 30
m i ni nt h ed a r k .A f t e ri n c u b a t i o n ,2m Lo fP B S / B S A
were added to each sample. Cells were harveshed and
resuspended in PBS/1%Formol. For every condition,
20.000 events were acquired using a FACSCalibur Flow
Cytometer (Becton Dickinson, USA) and analyzed using
CellQuest v.3.1 Software (Becton Dickinson, USA).
Results are expressed as mean relative fluorescence
intensity (MRFI), which was calculated by subtracting
the mean fluorescence intensity (MFI) for specific anti-
body by the MFI of the respective, isotype control. All
experiments were performed in triplicate.
Cell viability assay
Aliquots of IM-treated cells were removed after 24 h of
treatment. The number of viable cells was determined
using the trypan blue exclusion assay. The concentration
of drug necessary to achieve a 50% reduction of viable
cells was denoted as the IC50. All experiments were per-
formed in triplicate.
Apoptosis assays
To determine the percentage of apoptotic cells, we ana-
lyzed phosphatidyl serine externalization and membrane
integrity by double staining with Annexin V PE and 7-
AAD (PE Annexin V Apoptosis Detection Kit I, BD
Pharmingen, USA) according to manufacturer’s instruc-
tions. Briefly, after treatment, 1.0 × 10
5 cells were har-
vested, washed twice with cold PBS and resuspended in
100 μL of 1× binding buffer. Annexin V PE (5 μL) and
7-AAD (5 μL) were added, and samples were incubated
for 15 min in the dark. After incubation, 400 μLo f1 ×
binding buffer was added to each sample. Cells positive
for Annexin V PE and 7-AAD were considered apopto-
tic. For every condition, 20.000 events were acquired
using a FACSCalibur Flow Cytometer (Becton Dickin-
s o n ,U S A )a n da n a l y z e du s i n gC e l l Q u e s tv . 3 . 1S o f t w a r e
(Becton Dickinson, USA). All experiments were per-
formed in triplicate.
Cell cycle assays
Cell cycle was evaluated by staining with propidium
iodide (PI, Sigma-Aldrich) [80]. Approximately 3.0 × 10
5
cells were resuspended in 400 μL of hypotonic buffer
(3.4 mM Tris-HCl (pH 7.6), 10 mM NaCl, 0.1% (v/v)
NP-40, 700 U/L RNase, and 0.075 mM PI) and incu-
bated for 30 min at 4°C. For every condition, 5.000
events were acquired in a FACSCalibur Flow Cytometer
(Becton Dickinson, USA) and analyzed using Cell Quest
v.3.1 Software (Becton Dickinson, USA). All experiments
were performed in triplicate.
Pgp activity assay
Rho 123 (Sigma) was used to measure the activity of
Pgp by flow cytometry [81]. For each experiment, 1.0 ×
10
5cells were incubated with 200 ng/mL of Rho 123.
After 30 min of incubation at 37°C/5% CO2 cells were
washed with PBS and analyzed in a FACSCalibur Flow
Cytometer (Becton Dickinson, USA). For every condi-
tion, 20.000 events were acquired using a FACSCalibur
Flow Cytometer (Becton Dickinson, USA) and analyzed
using CellQuest v.3.1 Software (Becton Dickinson,
USA). Results are expressed as MFI. All experiments
were performed in triplicate.
Bone marrow samples
All bone marrow samples were obtained from CML
patients in all disease phases (CB, AP, or BP) and
donors admitted or registered at the Instituto Nacional
de Câncer (Rio de Janeiro, Brazil), according to the
guidelines of the local Ethics Committee and the
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(mean age = 30, range = 20-37, male:female ratio = 4:2),
5 IM-responsive patients (mean age = 45, range = 33-
52, male:female ratio = 5:0, CP:AP:BP ratio = 3:2:0) and
9 IM-resistant patients (mean age = 44, range = 26-61,
male:female ratio = 5:4, CP:AP:BP ratio = 1:4:4). Diag-
noses and follow-ups were based on hematologic, cyto-
genetic and molecular assays. IM-responsive patients
exhibited a major molecular response and complete
hematologic and cytogenetic response, whereas IM-
resistant patients lacked hematologic, cytogenetic and
molecular responses. The inclusion criterion was to
investigate CML patients that received IM as a first-line
therapy. Marrow aspirates were collected in heparinized
tubes and processed on the day they were collected.
Bone marrow mononuclear cells were isolated from 2-5
mL of aspirate in a Ficoll-Hypaque density gradient
(Ficoll 1.077 g/mL; GE, Sweden) according to manufac-
turer’sp r o t o c o l .C e l l sw e r ew a s h e d3t i m e si nP B Sa n d
subsequently used for RNA extraction.
2-DE
Cells were washed in PBS and resuspended in cold lysis
buffer containing 50 mM Tris (pH 7.5), 5 mM EDTA,
1 0m ME G T A ,5 0m MN a F ,2 0m Mb-glyceropho-
sphate, 250 mM NaCl, 2% NP-40 and protease inhibi-
tors and incubated on ice for 30 min. The lysates were
centrifuged at 12.000 g for 15 min at 4°C. The superna-
tants were collected, and the total protein concentra-
tions were determined by the Bradford assay [82]. Nine
hundred micrograms of total cell protein were precipi-
tated using a 2D cleanup kit (GE, Sweden) according to
manufacturer’si n s t r u c t i o n sa n dr e s u s p e n d e di nb u f f e r
containing 6 M Urea, 2 M Thiourea, 15 mM DTT, 2%
(w/v) ASB14, 0.5% IPG buffer (pH 3-10; GE, Sweden)
and bromophenol blue traces. IEF was carried out in an
11-cm Immobiline DryStrip (pH 4-7; GE, Sweden) on
an Ettan IPGphor III electrophoresis unit (GE, Sweden)
for a total of 32070 Vh. Subsequently, IPG strips were
equilibrated for 15 min in equilibration buffer (6 M
Urea, 30% (w/v) Glycerol, and 2% SDS in 0.05 M Tris-
HCl (pH 8.8) containing 100 mg DTT per 10 mL SDS
equilibration buffer) and then equilibrated for 15 min in
buffer containing 250 mg iodoacetamide. IPG strips
were run on ExcelGel SDS 8-18% gels according to pro-
cedures recommended by the manufacturer (GE, Swe-
den) and stained with colloidal blue [83]. All gels were
scanned with an Image scanner using LabScan v.5.0
software (GE, Sweden), and ImageMaster 2D Platinum
v.6.0 software (GE, Sweden) and subjected to visual ana-
lysis. pI values were determined using a linear 4-7 distri-
bution using a logarithmic curve. Molecular weight
values were determined using a Benchmark protein
standard (Invitrogen). 2-DE gels were analyzed
separately and averaged. For spots found in all gels, the
normalized spot volumes of triplicate samples were
averaged. Spot normalization is an internal calibration
that makes the data independent of experimental varia-
tions between gels caused by conditions such as differ-
ences in protein loading or staining. It was performed
with the use of relative Volume (%Vol) to quantify and
compare the gel spots. The intensity of each spot was
quantified by calculating the spot volume after normali-
zation of the image using the total spot volume normali-
zation method multiplied by the total area of all the
spots.
MS identification
The protein spots of interest were cut out of the gel and
processed for MS according to the following protocol.
The trimmed gels were washed three times in 50% acet-
onitrile (AcN) and 25 mM NH4 HCO3 (pH 8.0) for 15
min, soaked in 100% AcN and dried in a Speed-Vac for
30 min. The samples were rehydrated at 4°C in diges-
tion buffer (25 mM NH4 HCO3 (pH 8.0) containing 15
ng/μL porcine trypsin (Sequencing Grade Modified
Trypsin, Promega, USA)) and incubated at 37°C over-
n i g h t .T h ep e p t i d e sw e r ee x t r a c t e dw i t has o l u t i o no f
50% AcN and 5% Trifluoroacetic acid (TFA) and dried
in a Speed-Vac. Peptides were redissolved in 3 μLo f
50% AcN/1% TFA solution. For MALDI MS/MS analy-
sis, 0.5 μL of the redissolved peptide was mixed with
fresh cyano hydroxycinnamic acid as a matrix on a
MALDI plate. Mass spectra for peptide mass finger-
printing and confirmatory fragmentation analysis were
acquired using the MALDI-TOF-TOF instrument 4700
(Applied Biosystems, USA). MS data were acquired in
MALDI ion source, in positive ion reflector mode, mass
range 900-4000 Da, using a neodymium-doped yttrium
aluminum garnet (Nd: YAG) laser with a 200-Hz repeti-
tion rate and collision-induced dissociation (CID) mode
off. Capillary electrophoresis (CE) was not used. Typi-
cally, 1.600 shots were accumulated for spectra in MS
mode while 2.400 shots were accumulated for spectra in
MS/MS mode. Up to eight of the most intense ion sig-
nal was selected as precursors for MS/MS acquisition.
Spectra were acquired after plate calibration with cali-
bration mixture 1 or 2 (Sequazyme Peptide Mass Stan-
dards kit, PerSeptive Biosystems, USA).
Data processing and bioinformatics analysis
Peak lists were generated by Data Explorer v.4.5 soft-
ware (Applied Biosystems, USA) using default para-
meters and searched with Mascot Daemon v.2.1
software (Matrix Science) against the non-redundant
International Protein Index (IPI) protein sequence data-
base v.3.6 (80,412 entries, released 17.06.09). Search
parameters were as follows: database searches were
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ion mass tolerance of 0.2 Da, tryptic specificity allowing
for one missed cleavage, fixed modification of carbami-
domethylation of cysteine residues, and variable modifi-
cation of oxidation of methionine residues. The
criterion for positive protein identification was a mini-
mum of two peptides. The Mascot threshold (relied on
a 5% probability that the protein identification is incor-
rect) is a probability score. This score is described in
Supplemental Figure 1 for each protein identified. The
data associated with this manuscript may be down-
loaded from the http://ProteomeCommons.org Tranche
network using the following hash:
F6rVqTaM9oCMmblj4oHeNBhczim01D4sJYEw5AurF-
juk2n0WgLexO4PUOeJpB7RmFDDaPX + bbIxK-
Be1Vj7dbHgHjjX0AAAAAAACMpQ = =
These data include all MS files (.t2d format) from dif-
ferentially expressed proteins identified. Proteins were
investigated according to their GO http://www.geneon-
tology.com annotations based on molecular functions.
Functional analyses, network constructions and canoni-
cal pathway analyses were generated through the use of
IPA (Ingenuity
® Systems, http://www.ingenuity.com).
The following parameters were used: reference set
(Ingenuity knowledge Base - genes only); relationships
to consider (direct relationships); network generation
(mode on, 35 molecules per network); data sources (all);
confidence (consider only relationships that were experi-
mentally observed OR high predicted); species (human);
tissues and cell lines (all) and mutations (all).
Real-time quantitative PCR analysis
Analysis of mRNA levels was carried out by RT-qPCR.
Two micrograms of TRIzol- (Invitrogen) extracted RNA
from cell lines and healthy donor- and patient-derived
mononuclear bone marrow cells were reverse tran-
scribed with Superscript II Reverse Transcriptase
® (Invi-
trogen). cDNA dilutions (1:100) were mixed with SYBR
Green PCR Master Mix
® (Applied Biosystems, USA)
and the following forward (Fow) and reverse (Rev) pri-
mers: ABCB1 NM_000927.3 Fow 5’ CCCATCATTG-
CAATAGCAGG 3’,R e v5 ’ GTTCAAACTTCTGCTC
CTGA 3’; ABCG2 NM_004827.2 Fow 5’ TGGCTGTC
ATGGCTTCAGTA 3’,R e v5 ’ GCCACGTGATTCTTC-
CACAA 3’; OCT1 NM_003057.2 Fow 5’ TCCTCTTC
CTGCTCTACTACT 3’,R e v5 ’ ATGAAGGGCT-
CAGCTTTTCGG 3’; LRPPRC NM_133259.3 Fow 5’
GAGAGATGCCGGAATTGAGC 3’,R e v5 ’ CTCGG
ACTTCTCCACCTTCT 3’; MCM7 NM_005916.3 Fow
5’ TCGAGGCATGAAAATCCG GG 3’,R e v5 ’ CGCCA
GTCGATCAATGTATGACA 3’; RBM17 NM_032905.4
Fow 5’ GTGGGTTTGCAAGGAGACCAG3’,R e v5 ’
AAGTGGGTGGGGCAATGG 3’; ACTB NM_001101.3
Fow 5’ ACCTGAGAACTCCACTACCCT 3’,R e v5 ’
GGTCCCACCCATGTTCCAG 3’.R T - q P C Rw a sp e r -
formed in a Rotor Gene 6000 thermocycler (Cobertt)
with 50 cycles of 20 s at 95°C, 30 s at 60°C and 30 s at
72°C. For each sample, the expression of target genes
was normalized to b-actin mRNA levels. Changing
mRNA levels were evaluated as previously described
[84].
Statistical analysis
Cell viability, apoptosis activation, DNA content/cell
cycle and mRNA level differences between K562 and
Lucena were compared by a paired t-test. These statis-
tical analyses were performed using GraphPad Prism
®
v.5 software (GraphPad, USA). To determine if
increased mRNA levels were associated with IM resis-
tance, cut-off points for each gene were selected.
These cut-offs were determined by constructing ROC
curves with estimations of sensitivity, specificity and
area under the curve. Clinical information on IM resis-
tance was used as the state variable. The cut-off point
for each gene was established, and all values were cate-
gorized under or above these points. For univariate
analyses, Chi-squared and Fisher’s exact tests were
used to analyze the association between mRNA levels
and IM treatment outcome. For multivariate analyses,
logistic regression was performed to determine the
association between mRNA levels and IM therapy out-
come. These statistics were performed using SPSS
v.13.0 for Windows
® software (SPSS Inc.). P-V a l u e s
less than 0.05 were considered as statistically signifi-
cant (*p < 0.05, **p < 0.01, and ***p < 0.001).
Additional material
Additional file 1: Differentially expressed proteins identified in IM
cross-resistance. Proteins were separated into biological functions
according to GO analysis. Information regarding pI/MW, statistical and
Mascot score, number of identified peptides, peptide sequence and
sequence coverage were described.
Additional file 2: ROC curve. ROC curve analysis showed that ABCB1.
LRPPRC and MCM7 genes, together, are potential candidate biomarkers
for IM therapy response for further investigation. Area under curve (AUC):
0.733 (ABCB1); 0.550 (LRPPRC); 0.767 (MCM7).
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